With sentiment returning to Aussie biotechs in a massive way it looks like NRT will spike just like CMQ did. NRT is still very cheap compared to their potential unlike CMQ which is already around 50% of valuation.
Biotechs are also in favour in the USA with momentum strongly building in the smaller biotechs that have big potential.
Go Novogen!!
